SUTRO BIOPHARMA INC (STRO)
US8693671021 - Common Stock
Investors Snag STRO 6.3% Cheaper Than Its Secondary Stock Offering
Commit To Buy Sutro Biopharma At $2.50, Earn 12.9% Annualized Using Options
Sutro Biopharma Announces Pricing of $75 Million Underwritten Offering
SOUTH SAN FRANCISCO, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology...
STRO Stock Earnings: Sutro Biopharma Beats EPS, Beats Revenue for Q4 2023
STRO stock results show that Sutro Biopharma beat analyst estimates for earnings per share and beat on revenue for the fourth quarter of 2023.
STRO Stock Earnings: Sutro Biopharma Beats EPS, Beats Revenue for Q4 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Sutro Biopharma (NASDAQ:STRO) just reported results for the fourth quarter of 2...
Sutro Biopharma Reports Full Year 2023 Financial Results, Business Highlights and Select Anticipated Milestones
- Sutro highlighted luveltamab tazevibulin (luvelta) in a January 2024 investor webcast, describing the broad opportunity to address unmet needs in...
Sutro Biopharma to Participate in Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology...
Sutro Biopharma (STRO) Shares Cross Above 200 DMA
Commit To Buy Sutro Biopharma At $2.50, Earn 12.1% Annualized Using Options
Sutro Biopharma to Host Investor Webcast Highlighting Potential Multi-Cancer Opportunity for Luvelta, a FolRα-targeted ADC, on January 4, 2024
SOUTH SAN FRANCISCO, Calif., Dec. 14, 2023 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology...
Sutro Biopharma Announces New Positive Data from the Compassionate Use of Luveltamab Tazevibulin (luvelta) in Pediatric Patients with Relapsed/Refractory CBF/GLIS Presented at ASH 2023
– Complete remission seen in 42% of patients with CBF/GLIS AML with ≥5% blasts and 75% of pediatric patients with CBF/GLIS AML with <5% blasts;...
Sutro Biopharma to Participate in the JMP Securities Hematology and Oncology Summit
SOUTH SAN FRANCISCO, Calif., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology...
AbbVie-ImmunoGen M&A deal lifts ADC-focused biotechs
AbbVie&amp;#39;s (ABBV) $10.1B acquisition of Immunogen (IMGN) boosts shares of smaller biotech&amp;#39;s focused on antibody-drug conjugate (ADCs). Read more here.
Sutro Biopharma appoints Chung as its COO (NASDAQ:STRO)
Sutro Biopharma appoints Jane Chung as COO and president, effective December 1, 2023.
Sutro Biopharma Promotes Jane Chung to President and Chief Operating Officer
SOUTH SAN FRANCISCO, Calif., Nov. 21, 2023 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology...
Sutro Biopharma files for $300M mixed shelf (NASDAQ:STRO)
Sutro Biopharma files prospectus for mixed shelf offering of up to $xxM, signaling potential securities sale.
Sutro Biopharma Reports Third Quarter 2023 Financial Results, Business Highlights and Select Anticipated Milestones
- Updated luvelta data from Compassionate Use Access demonstrating anti-leukemic activity in pediatric patients with relapsed/refractory CBF2AT3-GLIS2 AML...
Sutro Biopharma Announces Presentation of Data for Luveltamab Tazevibulin (luvelta) from the Phase 1 Dose-Expansion Study in Endometrial Cancers at ESMO 2023
- Luvelta demonstrated encouraging preliminary anti-tumor activity (29% response rate) in late-stage patients with recurrent/relapsed endometrial cancer...
Sutro Demonstrates Meaningful ADC Innovation with Five Presentations and One Poster at the 14th Annual World ADC Conference
SOUTH SAN FRANCISCO, Calif., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology...
Commit To Purchase Sutro Biopharma At $2.50, Earn 6.1% Annualized Using Options
Sutro Biopharma Reports Second Quarter 2023 Financial Results, Business Highlights and Select Anticipated Milestones
- Enrollment is underway for REFRaME-O1, the Phase 2/3 pivotal study of luveltamab tazevibulin, or luvelta, for patients with platinum-resistant ovarian...